Serum levels of osteopontin predict major adverse cardiovascular events in patients with severe carotid artery stenosis. 2018

Federico Carbone, and Fabio Rigamonti, and Fabienne Burger, and Aline Roth, and Maria Bertolotto, and Giovanni Spinella, and Bianca Pane, and Domenico Palombo, and Aldo Pende, and Aldo Bonaventura, and Luca Liberale, and Alessandra Vecchié, and Franco Dallegri, and François Mach, and Fabrizio Montecucco
First Clinic of Internal Medicine, Department of Internal Medicine, University of Genoa School of Medicine, 6 viale Benedetto XV, 13132 Genoa, Italy. Electronic address: federico.carbone@edu.unige.it.

BACKGROUND Inflammatory mediators in the blood stream and within plaques are key determinants in atherogenesis. Here, we investigated serum osteopontin (OPN) as a potential predictor of poor outcome in patients with severe carotid atherosclerosis. METHODS Carotid plaques and serum were collected from patients asymptomatic (n=185) or symptomatic (n=40) for ischemic stroke. Plaques were stained for lipids, smooth muscle cells, neutrophils, M1 and M2 macrophage subsets and matrix metallopropteinase-9 (MMP-9). Serum levels of OPN and interleukin-6 (IL-6) were determined by colorimetric enzyme-linked immunosorbent assays. RESULTS Symptomatic patients showed a two-fold increase in serum OPN levels. In both symptomatic and asymptomatic patients, OPN levels positively correlated with intraplaque count of neutrophils, total macrophages, and MMP-9 content. In asymptomatic patients, OPN levels also positively correlated with lipids and M1 macrophage subsets. Receiver operating characteristic curve analysis identified serum OPN concentration of 70ng/ml as the best cut-off value to predict major adverse cardiovascular events (MACEs). Patients with high OPN levels had more vulnerable plaque phenotype and reduced levels of HDL-cholesterol and IL-6 as compared to low OPN levels. Kaplan-Meier curve confirmed that patients with OPN levels >70ng/ml had more MACEs at a 24-month follow-up. In the multivariate survival analysis, OPN levels >70ng/ml predicted MACEs, independently of age, gender, and symptomatic status. CONCLUSIONS High circulating OPN levels were strongly correlated with vulnerability parameters within plaques and predict MACEs in patients with severe carotid artery stenosis. Although confirmation is needed from larger trials, OPN could be a promising clinical tool to assess atherosclerotic outcomes.

UI MeSH Term Description Entries
D008297 Male Males
D011237 Predictive Value of Tests In screening and diagnostic tests, the probability that a person with a positive test is a true positive (i.e., has the disease), is referred to as the predictive value of a positive test; whereas, the predictive value of a negative test is the probability that the person with a negative test does not have the disease. Predictive value is related to the sensitivity and specificity of the test. Negative Predictive Value,Positive Predictive Value,Predictive Value Of Test,Predictive Values Of Tests,Negative Predictive Values,Positive Predictive Values,Predictive Value, Negative,Predictive Value, Positive
D002318 Cardiovascular Diseases Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM. Adverse Cardiac Event,Cardiac Events,Major Adverse Cardiac Events,Adverse Cardiac Events,Cardiac Event,Cardiac Event, Adverse,Cardiac Events, Adverse,Cardiovascular Disease,Disease, Cardiovascular,Event, Cardiac
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000369 Aged, 80 and over Persons 80 years of age and older. Oldest Old
D012720 Severity of Illness Index Levels within a diagnostic group which are established by various measurement criteria applied to the seriousness of a patient's disorder. Illness Index Severities,Illness Index Severity
D015331 Cohort Studies Studies in which subsets of a defined population are identified. These groups may or may not be exposed to factors hypothesized to influence the probability of the occurrence of a particular disease or other outcome. Cohorts are defined populations which, as a whole, are followed in an attempt to determine distinguishing subgroup characteristics. Birth Cohort Studies,Birth Cohort Study,Closed Cohort Studies,Cohort Analysis,Concurrent Studies,Historical Cohort Studies,Incidence Studies,Analysis, Cohort,Cohort Studies, Closed,Cohort Studies, Historical,Studies, Closed Cohort,Studies, Concurrent,Studies, Historical Cohort,Analyses, Cohort,Closed Cohort Study,Cohort Analyses,Cohort Studies, Birth,Cohort Study,Cohort Study, Birth,Cohort Study, Closed,Cohort Study, Historical,Concurrent Study,Historical Cohort Study,Incidence Study,Studies, Birth Cohort,Studies, Cohort,Studies, Incidence,Study, Birth Cohort,Study, Closed Cohort,Study, Cohort,Study, Concurrent,Study, Historical Cohort,Study, Incidence
D015415 Biomarkers Measurable and quantifiable biological parameters (e.g., specific enzyme concentration, specific hormone concentration, specific gene phenotype distribution in a population, presence of biological substances) which serve as indices for health- and physiology-related assessments, such as disease risk, psychiatric disorders, ENVIRONMENTAL EXPOSURE and its effects, disease diagnosis; METABOLIC PROCESSES; SUBSTANCE ABUSE; PREGNANCY; cell line development; EPIDEMIOLOGIC STUDIES; etc. Biochemical Markers,Biological Markers,Biomarker,Clinical Markers,Immunologic Markers,Laboratory Markers,Markers, Biochemical,Markers, Biological,Markers, Clinical,Markers, Immunologic,Markers, Laboratory,Markers, Serum,Markers, Surrogate,Markers, Viral,Serum Markers,Surrogate Markers,Viral Markers,Biochemical Marker,Biologic Marker,Biologic Markers,Clinical Marker,Immune Marker,Immune Markers,Immunologic Marker,Laboratory Marker,Marker, Biochemical,Marker, Biological,Marker, Clinical,Marker, Immunologic,Marker, Laboratory,Marker, Serum,Marker, Surrogate,Serum Marker,Surrogate End Point,Surrogate End Points,Surrogate Endpoint,Surrogate Endpoints,Surrogate Marker,Viral Marker,Biological Marker,End Point, Surrogate,End Points, Surrogate,Endpoint, Surrogate,Endpoints, Surrogate,Marker, Biologic,Marker, Immune,Marker, Viral,Markers, Biologic,Markers, Immune

Related Publications

Federico Carbone, and Fabio Rigamonti, and Fabienne Burger, and Aline Roth, and Maria Bertolotto, and Giovanni Spinella, and Bianca Pane, and Domenico Palombo, and Aldo Pende, and Aldo Bonaventura, and Luca Liberale, and Alessandra Vecchié, and Franco Dallegri, and François Mach, and Fabrizio Montecucco
November 2019, Atherosclerosis,
Federico Carbone, and Fabio Rigamonti, and Fabienne Burger, and Aline Roth, and Maria Bertolotto, and Giovanni Spinella, and Bianca Pane, and Domenico Palombo, and Aldo Pende, and Aldo Bonaventura, and Luca Liberale, and Alessandra Vecchié, and Franco Dallegri, and François Mach, and Fabrizio Montecucco
March 2018, Scientific reports,
Federico Carbone, and Fabio Rigamonti, and Fabienne Burger, and Aline Roth, and Maria Bertolotto, and Giovanni Spinella, and Bianca Pane, and Domenico Palombo, and Aldo Pende, and Aldo Bonaventura, and Luca Liberale, and Alessandra Vecchié, and Franco Dallegri, and François Mach, and Fabrizio Montecucco
July 2018, International journal of cardiology,
Federico Carbone, and Fabio Rigamonti, and Fabienne Burger, and Aline Roth, and Maria Bertolotto, and Giovanni Spinella, and Bianca Pane, and Domenico Palombo, and Aldo Pende, and Aldo Bonaventura, and Luca Liberale, and Alessandra Vecchié, and Franco Dallegri, and François Mach, and Fabrizio Montecucco
April 2021, Pharmacological research,
Federico Carbone, and Fabio Rigamonti, and Fabienne Burger, and Aline Roth, and Maria Bertolotto, and Giovanni Spinella, and Bianca Pane, and Domenico Palombo, and Aldo Pende, and Aldo Bonaventura, and Luca Liberale, and Alessandra Vecchié, and Franco Dallegri, and François Mach, and Fabrizio Montecucco
March 2018, Vascular pharmacology,
Federico Carbone, and Fabio Rigamonti, and Fabienne Burger, and Aline Roth, and Maria Bertolotto, and Giovanni Spinella, and Bianca Pane, and Domenico Palombo, and Aldo Pende, and Aldo Bonaventura, and Luca Liberale, and Alessandra Vecchié, and Franco Dallegri, and François Mach, and Fabrizio Montecucco
January 2017, Annals of vascular surgery,
Federico Carbone, and Fabio Rigamonti, and Fabienne Burger, and Aline Roth, and Maria Bertolotto, and Giovanni Spinella, and Bianca Pane, and Domenico Palombo, and Aldo Pende, and Aldo Bonaventura, and Luca Liberale, and Alessandra Vecchié, and Franco Dallegri, and François Mach, and Fabrizio Montecucco
April 2023, The Journal of dermatology,
Federico Carbone, and Fabio Rigamonti, and Fabienne Burger, and Aline Roth, and Maria Bertolotto, and Giovanni Spinella, and Bianca Pane, and Domenico Palombo, and Aldo Pende, and Aldo Bonaventura, and Luca Liberale, and Alessandra Vecchié, and Franco Dallegri, and François Mach, and Fabrizio Montecucco
January 2016, Mediators of inflammation,
Federico Carbone, and Fabio Rigamonti, and Fabienne Burger, and Aline Roth, and Maria Bertolotto, and Giovanni Spinella, and Bianca Pane, and Domenico Palombo, and Aldo Pende, and Aldo Bonaventura, and Luca Liberale, and Alessandra Vecchié, and Franco Dallegri, and François Mach, and Fabrizio Montecucco
October 2019, Vascular,
Federico Carbone, and Fabio Rigamonti, and Fabienne Burger, and Aline Roth, and Maria Bertolotto, and Giovanni Spinella, and Bianca Pane, and Domenico Palombo, and Aldo Pende, and Aldo Bonaventura, and Luca Liberale, and Alessandra Vecchié, and Franco Dallegri, and François Mach, and Fabrizio Montecucco
September 2023, Computers in biology and medicine,
Copied contents to your clipboard!